Volume 4, Issue 5

Managing MS Comorbidities: Beyond Pharmacologic Agents

In this issue:

The comorbidities associated with multiple sclerosis are known to significantly worsen inflammation and hasten disease progression. When relief with pharmacologic agents is inadequate, what concerns may hinder clinicians about turning to nonpharmacologic methods? 

How useful is neuromodulation in improving spasticity and gait dysfunction? Can behavioral training address MS-related cognition deficits? Is there anything more effective than the commonly prescribed medications to relieve MS fatigue? What does the evidence say? 

These are some of the key questions Dr. Oliver Tobin at the Mayo Clinic addresses in this issue of eMultipleSclerosis Review. 

Learning objectives:

  • Discuss specific comorbidities that affect diagnosis and prognosis in patients with MS and strategies for identification and treatment. 
  • Describe nonpharmacologic methods for treating the common multiple sclerosis symptoms of fatigue, spasticity, and gait dysfunction. 

Author:

W. Oliver Tobin, MB, BCh, BAO, PhD
W. Oliver Tobin, MB, BCh, BAO, PhD
Associate Professor, Neurology
Mayo Clinic
Rochester, MN

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: March 10, 2022
Expiration date: March 9, 2024